Process Intensification in AAV Gene Therapy, Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, learn about AAV biology and its use in cell and gene therapies. Attendees will gain insights about state-of-the-art production of cell and gene therapies. The featured speakers will discuss current process intensification methodology. The speakers will also discuss new strategies available to properly attenuate anti-viral defences in the production system: viral sensitizer technology.

One of the major bottlenecks, addressed in this webinar, is the problem of low manufacturing yield.

Gene therapy holds the potential to dramatically change healthcare for the better. Many of these viral therapies address patient populations that have no other options for treatment. AAV is one of the leading viral vectors for gene therapy applications, with a well-characterised safety profile, and (relatively) low immunogenicity. The initial approved gene therapy products on the market, such as Luxturna (2017) and Zolgensma (2019) utilize AAV as the delivery vehicle.

However, while new AAV therapies are being constantly developed, the manufacturing capacity for viral vectors is not able to address the demand. Some estimates indicate, for example, that the entire current capacity of the viral manufacturing industry is only capable of supplying a fraction of the viral vector doses needed to address Duchenne muscular dystrophy patients, a single disease indication. Novel solutions need to be applied to bottlenecks within the manufacturing process to supply the needs of patients waiting for these therapies. One of the major bottlenecks, addressed in this webinar, is the problem of low manufacturing yield.

Historically, viral manufacturers will focus on three major categories to increase yield: cell line and vector engineering, media optimization and bioreactor design. These methods often provide substantial increases to yield. However, none of them address antiviral defences in production cells. These defences actively attack and degrade foreign genetic material used to make viruses, as well as the viral products made by the cell. As a result, viral yield on a per-cell basis can be significantly affected.

Register for this webinar to learn about process intensification and the role of antiviral defences in AAV gene therapy systems.

Join Prof. Amine Kamen, Professor, McGill University; Dr. Sarah Wootton, Associate Professor, University of Guelph; and Dr. Jean-Simon Diallo, CEO, Virica Biotech, for the live webinar on Monday, November 14, 2022, at 2:30pm EST.

For more information, or to register for this event, visit Process Intensification in AAV Gene Therapy.


Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit
For information about hosting a webinar visit

Vera Kovacevic
Tel: +1 (416) 977-6555 x371

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Vera Kovacevic
+1 (416) 977-6555 x371
Email >
Visit website